MTOR and renal cell carcinoma: Another study [66] found that infiltrating TAMs induced RCC cells to develop resistance to sunitinib and mTOR inhibitors through high expression of T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) expression, and that TIM-3 on tumor and myeloid cells synergistically promoted the tumorigenic activity and enhanced the stem cell properties of RCC cells.